Affymax says phase 1 results promising for anemia drug Hematide

By E. Janene Geiss

Philadelphia, Sept. 15 - Affymax, Inc. said Friday that clinical data from a phase 1 trial demonstrated that single doses of Hematide resulted in dose-dependent increases in circulating reticulocytes in normal healthy volunteers and in a clinically and statistically significant increase in red blood cells and hemoglobin from baseline, which was sustained for at least one month.

The results are published in Friday's issue of Blood, a scientific journal.

Hematide, the Palo Alto, Calif.-based biopharmaceutical company's first product candidate to enter the clinic, is a novel peptide-based drug designed to stimulate the production of red blood cells.

It is in phase 2 trials for the treatment of anemia associated with chronic kidney disease and in anemic cancer patients undergoing chemotherapy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.